Thus, BCL6 has been associated with resistance to HDAC inhibitors in DLBCL [117], BCR-ABL1 kinase inhibitors in ALL [118], cytarabine in AML [99], paclitaxel in breast cancer [119], and BET inhibitors in KRAS+ non-small-cell lung cancer [120]. Here, BCL6 is linked to breast cancer.